GlassScriptPhysician profile
Nicholas Gourtzelis
NPI 1790734994
$8,883.76
in general payments reported to CMS, 2019-2025
34 companies · $1,680 in 2025
The $1,680 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $693 · 2021: $1,195 · 2022: $1,239 · 2023: $1,439 · 2024: $1,515 · 2025: $1,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,633.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,325.65 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $800.42 | 2019-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $797.76 | 2019-2024 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $743.08 | 2019-2025 | Farxiga |
| Amgen INC. | $667.11 | 2019-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $576.17 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $533.32 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $443.25 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $354.97 | 2020-2024 | Acthar, Terlivaz |
| Glaxosmithkline, LLC. | $310.35 | 2021-2025 | Benlysta, Jesduvroq |
| Fresenius USA Marketing, INC. | $268.21 | 2019-2025 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.50 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $190.08 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $185.02 | 2022-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $181.65 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $135.25 | 2019 | |
| Aurinia Pharma U.S., INC. | $124.08 | 2021-2023 | Lupkynis |
| Pharmacosmos Therapeutics INC. | $119.17 | 2021-2023 | Monoferric |
| Novo Nordisk INC | $102.66 | 2025 | Ozempic, Rybelsus |
| Vantive US Healthcare LLC | $101.31 | 2025 | Renal - Acute, Renal - Pd |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $97.92 | 2022-2025 | Voyxact |
| Daiichi Sankyo INC. | $97.27 | 2022-2023 | Injectafer |
| Ardelyx, INC. | $85.29 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $76.77 | 2020-2023 | Gattex |
| E.R. Squibb & Sons, L.L.C. | $75.90 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $74.80 | 2025 | Purified Cortrophin Gel |
| Cormedix INC. | $32.62 | 2024 | Defencath |
| Shire North American Group INC | $30.76 | 2019 | |
| Baxter Healthcare | $27.10 | 2024 | Renal - Pd |
| Recor Medical INC | $25.48 | 2025 | Paradise Ultrasound Renal Denervation System |
| Ascendis Pharma Endocrinology INC | $23.59 | 2025 | Yorvipath |
| Lemaitre Vascular, INC. | $21.05 | 2025 | Artegraft Vascular Graft |
| Scpharmaceuticals INC. | $20.22 | 2025 | |
| Shield Therapeutics INC | $13.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Gourtzelis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.